Highlights

• FY26 underlying net profit fell 22% to A$322.4 million, near the top of the revised range.

• FY27 underlying net profit guidance is A$330 million to A$350 million, implying modest growth from a lower base.

• The Nucleus Nexa System made up more than 95 per cent of developed-market implant sales by June.

• A Shareholder class action and a chair succession process add to the uncertainty facing the company.

Why is Cochlear (ASX:COH), long treated as one of the steadiest Growth Stocks on the ASX, now being judged on whether it can simply stabilise? The short answer is that a profit downgrade in April 2026 broke the market's confidence, and the company's results, guidance and Annual General Meeting since then have been about rebuilding it one step at a time.

The hearing-implant maker reported FY26 underlying net profit of A$322.4 million on 18 August 2026, down 22 per cent and near the top of its revised range. For FY27 it is guiding to A$330–350 million. That is modest growth from a much lower base, and it comes with a shareholder class action, a chair succession process and softer hearing-health markets in the background.

From defensive favourite to decade low

The turning point came on 22 April 2026. Cochlear cut its FY26 Underlying Profit guidance to A$290–330 million, from A$435–460 million issued about two months earlier. It cited US volumes that weakened from mid-February, surgical waiting lists and hospital capacity limits in the UK and Germany, industrial action in Italy and Spain, and a stronger Australian dollar.

The market reaction was severe.

That remains less than half the earlier highs.

What Cochlear sells and where the money comes from

Cochlear designs and manufactures implantable hearing devices. Cochlear implants made up 61 per cent of FY26 sales Revenue at A$1,435.2 million, flat in constant currency even though implant units rose 5 per cent to 56,692.

Services, mainly sound processor upgrades for existing recipients, contributed A$634.9 million, or 27 per cent, and grew 6 per cent in constant currency. Acoustics, which includes bone conduction devices, added A$273.3 million. Group sales revenue was A$2,343.4 million, down 1 per cent as reported and up 2 per cent in constant currency.

The services line matters because it is tied to a large installed base of recipients rather than new surgeries. That recurring element helped cushion the weaker implant result.

Inside the FY26 numbers

The headline profit decline hides some offsetting strengths. Operating Cash Flow rose by A$130.4 million to A$368.0 million, and free cash flow was A$263.5 million. Net cash finished at A$187.7 million.

Margins, however, went the wrong way. Gross Margin fell from 74 per cent to 71 per cent and net profit margin from 18 per cent to 14 per cent, while operating expenses of A$1,251.4 million included about A$69 million of transitional costs. Statutory net profit fell 62 per cent to A$147.3 million.

Regional pressure and the Nexa launch

Results varied sharply by region. US revenue grew 4 per cent and Cochlear said it held share, although it described market growth as softer, citing insurance approval delays and pressure on healthcare budgets. Western Europe fell 8 per cent, and emerging markets slipped 2 per cent in constant currency as conflict affected the Middle East.

China is a structural headwind. Volume-based procurement has lifted unit numbers but reduced average selling prices, and Cochlear also flagged reimbursement cuts in special access zones from the second half.

The brightest spot is the Nucleus Nexa System, which Cochlear describes as the world's first smart cochlear implant system with upgradeable firmware. By June it made up more than 95 per cent of developed-market implant sales and delivered an average price increase of about 3 per cent. Whether that pricing holds while volumes recover is a central question.

The FY27 roadmap and the AGM

Alongside the FY27 profit range, Cochlear expects low single-digit constant-currency revenue growth, a gross margin of about 70–71 per cent, slightly lower reported operating expenses and Capital Expenditure of A$100–110 million. It assumes an Australian dollar of 70 US cents, which it estimates will reduce underlying profit by about 10 per cent against FY26 average rates.

Management has also restated a medium-term goal of returning the net profit margin to 18 per cent. That target depends on cost discipline and on surgery volumes improving in the US and Europe.

The same account said chair succession was underway with external help, and reported no protest vote against the remuneration report.

Legal and market risks to weigh

The claim covers investors who bought shares between 15 August 2025 and 21 April 2026. The company denies the allegations and intends to defend the case.

Beyond litigation, the company's own disclosures point to a further rise in the Australian dollar, continued pricing pressure in China, slower adult implant referrals in the US, and European hospital capacity constraints that Cochlear does not control.

What to watch

The next marker is the half-year result due in February 2027, which will show whether Nexa pricing, services growth and cost savings are enough to offset weaker markets. Investors will also watch for progress on the class action and the appointment of a new chair.